GLSI - Greenwich LifeSciences Inc Ordinary Shares (Healthcare: Biotechnology) Projected Earnings Date: 2024-08-26    (Delayed quote data   2025-07-10)
Last
 11.22		 Change
 ⇑ +0.67   (+6.35%)		 Volume
  72,635
Open
 10.46		 High
 11.29		 Low
 10.45
8EMA (Daily)
 10.09		 40EMA (Daily)
 9.66		 50EMA (Daily)
 9.73		 STO (Daily)
 93.568		 MACD Hist (Daily)
 0.490
8EMA (Weekly)
 9.920		 40EMA (Weekly)
 11.19		 50EMA (Weekly)
 11.48		 STO (Weekly)
 46.525		 MACD Hist (Weekly)
 0.389
Company Profile
Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com